Back to search

Article

Specific <i>BRCA</i> and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas

2021-08-19

Abstract excerpt

<h4>SUMMARY</h4> Loss of homologous recombination repair (HRR) via germline and somatic BRCA1 or BRCA2 gene mutations and via BRCA1 promoter methylation has been associated with better response to platinum agents and PARP inhibitors, in both triple negative breast cancer (TNBC) and ovarian carcinoma (OvCa). A major conundrum arising from recent clinical studies is why cancers with BRCA1 promoter methylation (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
078a8dd9-4fb2-564e-be01-b6cacc30a14b
DOI
10.1101/2021.08.19.456799
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Specific <i>BRCA</i> and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomasDOI 10.1101/2021.08.19.456799
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.Semantic proximity
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Semantic proximity
<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerSemantic proximity
Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.Semantic proximity
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialSemantic proximity
BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.Semantic proximity
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitorsSemantic proximity
Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaSemantic proximity
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerSemantic proximity
The epigenetic response to platinum-induced DNA damage and repairSemantic proximity
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian CancerSemantic proximity
Select a neighboring publication to make it the new centre.